Clinical Trial Detail

NCT ID NCT03878199
Title Cytarabine and Daunorubicin in Combination With Ruxolitinib for the Treatment of Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

CPX-351 + Ruxolitinib

Age Groups: adult senior

No variant requirements are available.